Page last updated: 2024-12-05

1,2-dipalmitoylphosphatidylcholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 1,2-Dipalmitoylphosphatidylcholine (DPPC)

1,2-Dipalmitoylphosphatidylcholine (DPPC) is a type of **phospholipid**, a key component of cell membranes. It is a **saturated** phospholipid, meaning its fatty acid tails are fully saturated with hydrogen atoms, giving it a **straight and rigid structure**.

**Structure:**

* **Phosphatidylcholine (PC) head group:** This is the hydrophilic (water-loving) part of the molecule. It consists of a phosphate group linked to choline.
* **Two palmitoyl (C16:0) chains:** These are the hydrophobic (water-repelling) fatty acid tails.

**Importance in Research:**

DPPC is crucial for research due to its following properties:

* **Model membrane formation:** It readily forms stable **lipid bilayers** in vitro, mimicking the structure of cell membranes. This makes it a valuable tool for studying:
* **Membrane properties:** Permeability, fluidity, and interactions with other molecules.
* **Drug delivery:** Testing the interactions of drugs with membranes.
* **Protein-membrane interactions:** Examining how proteins interact with and integrate into membranes.
* **Membrane fusion and fission:** Investigating the processes of vesicle formation and cell signaling.
* **Surface tension reduction:** DPPC is a **surfactant** and lowers the surface tension of water. This property is used in studies of:
* **Lung surfactant:** DPPC is the major component of lung surfactant, essential for lung function and reducing surface tension in alveoli.
* **Drug delivery:** Surfactants help to improve drug absorption and delivery.
* **Biocompatibility:** DPPC is generally considered **biocompatible**, meaning it is not toxic to cells and tissues. This makes it suitable for various biomedical applications, such as:
* **Nanoparticle formulation:** DPPC can be used to create nanoparticles for drug delivery or imaging.
* **Biomaterial development:** DPPC can be incorporated into biomaterials for tissue engineering and other medical applications.

**Applications in Specific Research Areas:**

* **Drug delivery:** DPPC-based liposomes are commonly used to deliver drugs and other therapeutic agents.
* **Lung research:** DPPC is used to study the function of lung surfactant and to develop therapies for respiratory diseases.
* **Nanotechnology:** DPPC is used in the development of nanoparticles for drug delivery, imaging, and other biomedical applications.
* **Biophysics:** DPPC is used to study the physical properties of membranes, such as fluidity and permeability.

**Overall, DPPC is a versatile and valuable tool for research in various fields, from cell biology and drug delivery to nanotechnology and biophysics.** Its ability to mimic cell membranes and its biocompatibility make it an ideal component for numerous research applications.

1,2-Dipalmitoylphosphatidylcholine: Synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of PULMONARY SURFACTANTS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6138
SCHEMBL ID184776
MeSH IDM0023172

Synonyms (78)

Synonym
1,2-dipalmitoyl-rac-glycero-3-phosphocholine
D-6051
D-6048
2644-64-6
2,3-bis(palmitoyloxy)propyl-2-(trimethylammonio)ethylphosphat
2,3-di(hexadecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
1,2-dipalmitoylphosphatidylcholine
3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxohexadecyl)oxy)-, inner salt, 4-oxide
choline, hydroxide, dihydrogen phosphate, inner salt, ester with 1,2-palmitin
dl-beta,gamma-dipalmitoyl-alpha-lecithin
beta,gamma-dipalmitoyl-dl-alpha-lecithin
1,2-dipalmitoylglycerol-3-phosphorylcholine
1,2-dipalmitoylglycerophosphorylcholine
1-palmitoyl-2-palmitoylphosphatidylcholine
(+-)-beta,gamma-dipalmitoyl-alpha-lecithin
dihexadecanoyl phosphatidylcholine
beta,gamma-dipalmitoyl-dl-phosphatidylcholine
1,2-dipalmitoyl-alpha-phosphatidylcholine
1,2-dipalmitoyllecithin
dl-dipalmitoyl-alpha-lecithin
1,2-dipalmitoyl-dl-phosphatidylcholine
unii-2w15rt5v7v
1,2-dipalmitoyl-dl-alpha-phosphatidylcholine
choline, phosphate, ester with 1,2-dipalmitin
rac-1,2-dipalmitoylglycerol-3-phosphorylcholine
beta,gamma-dipalmitoyllecithin
dl-1,2-dipalmitoyl-3-phosphatidylcholine
1,2-dihexadecanoyl phosphatidylcholine
1,2-dihexadecanoyl-rac-glycerol-3-phosphrylcholine
dl-beta,gamma-dipalmitoyl-alpha-phosphatidylcholine
einecs 220-530-8
beta,gamma-dipalmitoyl-dl-alpha-phosphatidylcholine
dl-dipalmitoylphosphatidylcholine
coatsome mc 6060
1,2-dipalmitoyl-3-phosphatidyl choline
beta,gamma-dipalmitoyl-dl-alpha-glycerylphosphorylcholine
3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxohexadecyl)oxy)-, hydroxide, inner salt, 4-oxide
dl-alpha-dppc
alpha,beta-dipalmitoylphosphatidylcholine
einecs 220-153-9
dipalmitoyl-dl-alpha-phosphatidylcholine
(4-oxido-10-oxo-7-palmitoyl-3,5,9-trioxa-4-phosphapentacosyl)trimethylammonium 4-oxide
rac-1,2-dipalmitoylphosphatidylcholine
dl-3-dipalmitoylphosphatidylcholine
alpha-glycerophosphorylcholine, beta,gamma-palmitoyl-
dppc (phosphatide)
2w15rt5v7v ,
FT-0603263
FT-0625422
FT-0625444
HMS3370B08
dipalmitoyl lecithin, dl-
1,2-dipalmitoylphosphatidylcholine, dl-
dipalmitoylphosphatidylcholine, (+/-)-
dipalmitoylphosphatidylcholine, dl-
dppc, dl
rac-1,2-dipalmitoylglycero-3-phosphocholine
SCHEMBL184776
2797-68-4
1,2-dihexadecanoyl-rac-glycero-3-phosphocholine
l-alpha-dipalmitoyl lecithin
GS-6140
(2-{[2,3-bis(hexadecanoyloxy)propyl phosphono]oxy}ethyl)trimethylazanium
mfcd00066101
dl-,-dipalmitoyl--lecithin
BCP08131
2,3-dihexadecanoyl-sn-glycero-1-phosphocholine
Q2587934
2,3-bis(palmitoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate
1,2-dipalmitoyl-rac-glycero-3-phosphocholine;dppc (phosphatide)
BCP30980
SY057411
dl-alpha-phosphatidylcholine
DTXSID50910226
2,3-bis(hexadecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
AKOS037653252
1,2-dipalmitoyl-sn-glycero-3-phosphochol
1,2-dipalmitoyl-d62-sn-glycero-3-phosphocholine-1,1,2,2-d4-n,n,n-trimethyl-d 9

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Stearylamine- and cardiolipin-containing liposomes were toxic (ID50) at 200 microM liposomal lipid concentrations or less, whereas phosphatidylglycerol- and phosphatidylserine-containing liposomes were toxic in the range 130-3000 microM."( Toxicity of non-drug-containing liposomes for cultured human cells.
Ito, M; Lazo, R; Mayhew, E, 1987
)
0.27
" These novel biodegradable particles are biocompatible in and around the brain, and may be safe for intracranial sustained drug delivery either in the parenchyma or into the CSF."( Lipid-sugar particles for intracranial drug delivery: safety and biocompatibility.
Kohane, DS; Langer, R; Le, D; Moskowitz, MA; Plesnila, N; Thomas, SS, 2002
)
0.31
"The aim of this study was to evaluate adverse effects of multiwalled carbon nanotubes (MWCNT), produced for industrial purposes, on the human epithelial cell line A549."( Adverse effects of industrial multiwalled carbon nanotubes on human pulmonary cells.
Amara, N; Boczkowski, J; Bussy, C; Grodet, A; Lanone, S; Pairon, JC; Rossi, MJ; Setyan, A; Tabet, L, 2009
)
0.35
"The results of this study suggest that fusogenic liposomal preparation of CyA is safe and can be useful for future studies."( Safety evaluation of nanoliposomes containing cyclosporine a after ocular administration.
Abedini, E; Ashraf, H; Banaee, T; Farzadnia, M; Malaekeh-Nikouei, B; Mosallaei, N, 2012
)
0.38
"Once inhaled, nanoparticles (NPs) will first interact with lung surfactant system, which may influence the colloidal aspects of NPs and consequently the toxic potential of NPs to pulmonary cells."( Toxicity of ZnO nanoparticles (NPs) to A549 cells and A549 epithelium in vitro: Interactions with dipalmitoyl phosphatidylcholine (DPPC).
Cao, Y; He, T; Li, J; Liu, L; Long, J, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
" Both in vitro techniques gave similar results which are consistent with previous findings on the pharmacokinetic behavior of ZnPc."( A comparison of fluorescence methods used in the pharmacokinetic studies of Zn(II)phthalocyanine in mice.
Biolo, R; Jori, G; Kennedy, JC; Nadeau, P; Pottier, R; Reddi, E; Weagle, G, 1991
)
0.28
" When this technique is applied to mice that have been fed on a normal chlorophyll-based diet, and particularly when measurements are performed in the abdominal region, oscillations are sometimes observed superimposed on the pharmacokinetic curve of the ZnPc."( On the source of the oscillations observed during in vivo zinc phthalocyanine fluorescence pharmacokinetic measurements in mice.
Gudgin Dickson, EF; Holmes, H; Jori, G; Kennedy, JC; Nadeau, P; Pottier, RH; Rossi, F; Russell, DA; Weagle, GE, 1995
)
0.29
" The pharmacokinetic parameters for the free and for the liposomal prodrugs fitted a bi-exponential plasma disposition."( Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel.
Arpicco, S; Brusa, P; Cattel, L; Ceruti, M; Crosasso, P; Dosio, F, 2000
)
0.31
" A quantitative pharmacokinetic description of particulate drug forms requires serious adjustments in existing theoretical approaches, due to formulation size."( Pharmacokinetics of liposomes designed to carry glucocorticoids.
Hrynyk, R; Langner, M; Metselaar, B; Storm, G,
)
0.13
" Pharmacodynamic studies were conducted to determine duration of effect."( Manufacture, characterization, and pharmacodynamic evaluation of engineered ipratropium bromide particles.
Hickey, AJ; Taylor, MK; VanOort, M, 2006
)
0.33
" In this study, the pharmacokinetic behavior of liposomes coated with the poly(amino acid) poly(hydroxyethyl-l-asparagine) (PHEA) was evaluated at low lipid doses and upon repeated administration in rats."( Pharmacokinetics of poly(hydroxyethyl-l-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration.
Carstens, MG; Hennink, WE; Oussoren, C; Romberg, B; Snel, CJ; Storm, G, 2007
)
0.34
"The safety and pharmacokinetic profile of liposomal formulations containing combinations of the antioxidants α-tocopherol, γ-tocopherol or N-acetylcysteine in beagle dogs was examined."( Safety and pharmacokinetic studies of liposomal antioxidant formulations containing N-acetylcysteine, α-tocopherol or γ-tocopherol in beagle dogs.
Alipour, M; Bolger, G; Mitsopoulos, P; Pucaj, K; Smith, MG; Suntres, ZE, 2013
)
0.39

Compound-Compound Interactions

ExcerptReferenceRelevance
" Accordingly, the drugs could be classified as: hydrophilic ones situated in the aqueous core and which may interact with the head groups; those located at the water-bilayer interface with some degree of penetration into the lipid bilayer; those lipophilic drugs constrained within the bilayer."( Drug interaction and location in liposomes: correlation with polar surface areas.
Barry, BW; El Maghraby, GM; Williams, AC, 2005
)
0.33
" In addition, both in vitro and in vivo studies indicated that the SIN-TSL combined with microwave hyperthermia exhibited superior anti-rheumatoid arthritis effect."( Sinomenine hydrochloride loaded thermosensitive liposomes combined with microwave hyperthermia for the treatment of rheumatoid arthritis.
Du, Y; Qi, J; Shen, Q; Shu, G; Ying, X; Zhang, X, 2020
)
0.56
" These combined results lead to the conclusion that this lipophilic compound may interact with the lipidic layers, preferentially at the lipid-air interface, to minimize the free energy, and reaches this conformation disturbing the thermodynamic, structural, mechanical, rheological, and morphological properties of the well-packed DPPC monolayer."( Sakuranetin interacting with cell membranes models: Surface chemistry combined with molecular simulation.
Amaral de Siqueira, LJ; Caseli, L; da Cruz Ramos Pires, GH; Freire, VT; Lago, JHG; Pereira, RG; Umehara, E, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" Interactions of surfactant and mineral surface functional groups responsible for the mineral-specific rate differences, and implications for determining the mineral surface bioavailability of silica and silicate dusts, are discussed."( Contrasting respirable quartz and kaolin retention of lecithin surfactant and expression of membranolytic activity following phospholipase A2 digestion.
Hill, CA; Keane, MJ; Mike, PS; Regad, ED; Vallyathan, V; Wallace, WE, 1992
)
0.28
" The two absorption rate constants differed by more than an order of magnitude."( The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man.
Kellaway, IW; Stevens, J; Taylor, G; Taylor, KM, 1989
)
0.28
"Topical bioavailability of drugs incorporated in liposomes is not well known."( Cutaneous bioavailability in hairless rats of tretinoin in liposomes or gel.
Bonte, F; Masini, V; Meybeck, A; Wepierre, J, 1993
)
0.29
"The mucoadhesiveness of polymer-coated liposomes was evaluated to develop a novel drug carrier system for oral administration of poorly absorbed drugs such as peptide drugs."( Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes.
Hino, T; Kawashima, Y; Niwa, T; Takeuchi, H; Yamamoto, H, 1996
)
0.29
" In the present study, we evaluated the potential of omeprazole to interfere with the bioavailability of aspirin administered to rats either alone or complexed with the zwitterionic phospholipid, dipalmitoylphosphatidylcholine (DPPC)."( Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats.
Dial, EJ; Felder, TB; Giraud, MN; Illich, PA; Lichtenberger, LM; Sanduja, SK, 1997
)
0.3
"Gastric absorption of aspirin and its relative bioavailability were reduced by an antisecretory dose of omeprazole; its inhibitory effect on gastric prostaglandin synthesis was consequently attenuated."( Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats.
Dial, EJ; Felder, TB; Giraud, MN; Illich, PA; Lichtenberger, LM; Sanduja, SK, 1997
)
0.3
" We hypothesized that cholesterol thermodynamic activity (A(t)) would predict bioavailability of cholesterol monomers in intestinal content, and that natural dietary phospholipids exhibiting high affinity for cholesterol would reduce its absorption."( Dietary sphingomyelin suppresses intestinal cholesterol absorption by decreasing thermodynamic activity of cholesterol monomers.
Carey, MC; Donovan, JM; Eckhardt, ER; Wang, DQ, 2002
)
0.31
" The absolute PTH bioavailability was 21% after intratracheal administration of the powder formed of PTH/albumin/lactose/dipalmitoylphosphatidylcholine and 18% after subcutaneous injection in rats."( Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats.
Arras, M; Codrons, V; Lison, D; Préat, V; Vanbever, R; Vanderbist, F; Verbeeck, RK, 2003
)
0.32
"Vitamin K1 is poorly absorbed by the oral route in certain diseased conditions."( Quantitative effects of interacting variables on vitamin K1, phylloquinone, entrapment in liposomes.
Onaga, IC; Oyenuga, KO, 2001
)
0.31
"Various xenobiotics interact with biological membranes, and precise evaluations of the molecular interactions between them are essential to foresee the toxicity and bioavailability of existing or newly synthesized molecules."( Probing nanomechanical interaction at the interface between biological membrane and potentially toxic chemical.
Hwang, DS; Ko, J; Lee, DW; Lim, C; Park, J; Park, S, 2018
)
0.48
" The results of the study are relevant to the problem of the low bioavailability of bioactive peptides (BP)."( Interaction mechanism of egg derived peptides RVPSL and QIGLF with dipalmitoyl phosphatidylcholine membrane: microcalorimetric and molecular dynamics simulation studies.
Fan, Y; Ji, H; Ma, W; Yu, Z; Zhao, W, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" We conclude that after giving two doses of Exosurf, further doses might best be delayed until after two days, and that further clinical evaluation of dosage regimens is required."( Turnover of exogenous artificial surfactant.
Ashton, MR; Austin, NC; Hall, MA; Normand, IC; Postle, AD; Smith, DE, 1992
)
0.28
" Ongoing trials may identify whether prophylactic or rescue administration of the surfactant preparation is the preferred approach and whether different dosage regimens or different administration techniques impart greater therapeutic efficacy."( Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.
Dechant, KL; Faulds, D, 1991
)
0.28
" Alkanols longer than C10 showed biphasic dose-response curves."( High pressure antagonism of alcohol effects on the main phase-transition temperature of phospholipid membranes: biphasic response.
Kamaya, H; Kaminoh, Y; Tamura, K; Ueda, I, 1991
)
0.28
" Only one therapy, multiple dosing with drug loaded sonicated vesicles, liposomes or niosomes, was found to be effective against parasites in the liver, spleen and bone marrow."( Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice.
Alexander, J; Baillie, AJ; Carter, KC; Dolan, TF; McColgan, C, 1989
)
0.28
" Severe intestinal ulcers resulted following oral administration of indomethacin in either vehicle at daily 3-4-mg/kg doses, but did not result from EPCMPV formulations, whether dosed for 4 days or 14 days."( Encapsulation of indomethacin in liposomes provides protection against both gastric and intestinal ulceration when orally administered to rats.
Fielder, FG; Ginsberg, RS; Godin-Ostro, E; Slusher, MA; Soehngen, EC; Weiner, AL, 1988
)
0.27
" Carnitine, in the novel dosage form, accumulated to a higher extent in the liver (156%) and spleen (336%), while the concentration in lung (52%), heart (55%) and muscle tissue (54%) decreased markedly relative to the standard."( Pharmacokinetics and organ distribution of liposome-encapsulated L-carnitine in rats.
Jäger, W; Koch, HP, 1993
)
0.29
" There were no significant differences among the three dosage groups in mortality rate, air leak, bronchopulmonary dysplasia, and other complications of prematurity."( Comparison of the effect of three doses of a synthetic surfactant on the alveolar-arterial oxygen gradient in infants weighing > or = 1250 grams with respiratory distress syndrome. American Exosurf Neonatal Study Group II.
Berry, DD; Buchter, DS; Easa, D; Edwards, K; Kanarek, KS; Kopelman, AE; Long, W; Philips, JB; Pramanik, AK, 1994
)
0.29
" Dose-response analyses employing the fever model demonstrated that potency of aspirin to reduce fever was increased 5 to 10-fold when the aspirin was intragastrically administered in the lipid-associated state."( Zwitterionic phospholipids enhance aspirin's therapeutic activity, as demonstrated in rodent model systems.
Dial, EJ; Illich, PA; Lichtenberger, LM; Romero, JJ; Ulloa, C; Vanous, AL; Walters, ET, 1996
)
0.29
" Further research needs to be performed to determine the optimal dosing and timing of these agents, as well as comparative trials studying efficacy."( Exogenous surfactant use in neonates.
Ishisaka, DY, 1996
)
0.29
" This method could be a valuable tool for studying: (1) therapies that enhance lung/surfactant maturation; (2) the dosing and timing of surfactant therapy in different lung diseases; and (3) the comparison of different surfactant preparations."( Exogenous surfactant kinetics in infant respiratory distress syndrome: A novel method with stable isotopes.
Badon, T; Carnielli, VP; Cavicchioli, P; Cogo, PE; Giordano, G; Sauer, PJ; Torresin, M; Zacchello, F; Zimmermann, LJ, 2000
)
0.31
" The dosage occurred through a purpose-built administration device."( Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma.
Babu, KS; Conway, JH; Holgate, ST; Smith, SE; Staniforth, JN; Woodcock, DA, 2003
)
0.32
" The two populations differ in their accumulation capacities, dosage and time constants."( Pharmacokinetics of liposomes designed to carry glucocorticoids.
Hrynyk, R; Langner, M; Metselaar, B; Storm, G,
)
0.13
" Although the mechanisms behind these observations are still not clear yet, the use of PHEA-liposomes appears beneficial when single low lipid doses and/or repeated dosing schedules are being applied."( Pharmacokinetics of poly(hydroxyethyl-l-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration.
Carstens, MG; Hennink, WE; Oussoren, C; Romberg, B; Snel, CJ; Storm, G, 2007
)
0.34
" The results from this study can be applied as a model for the development of a gene-therapeutic dosage form."( Expression of luciferase plasmid (pCMVLuc) entrapped in DPPC/cholesterol/DDAB liposomes in HeLa cell lines.
Manosroi, A; Manosroi, J; Peschka-Süss, R; Schubert, R; Thathang, K; Werner, RG, 2009
)
0.35
"A novel dialysis adapter has been developed for USP apparatus 4 for in vitro release testing of dispersed system dosage forms."( A novel USP apparatus 4 based release testing method for dispersed systems.
Bhardwaj, U; Burgess, DJ, 2010
)
0.36
" At a higher dosage range, the highest anti-biofilm activity was achieved by LCS with liposomal particle size of 800 nm."( Liposome combined porous beta-TCP scaffold: preparation, characterization, and anti-biofilm activity.
Ding, J; Li, J; Shi, J; Xu, YQ; Zhu, CT, 2010
)
0.36
" This failure may relate to a number of factors, among them inadequacy of pharmaceutical surfactants, insufficient dosing or drug delivery, poor drug distribution, or simply an inability of the drug to substantially impact the underlying pathophysiology of ALI/ARDS."( The future of exogenous surfactant therapy.
Notter, RH; Willson, DF, 2011
)
0.37
" The dogs in the control group (EL) and three test groups exhibited no signs of toxicity during the dosing period or day 15 post treatment."( Safety and pharmacokinetic studies of liposomal antioxidant formulations containing N-acetylcysteine, α-tocopherol or γ-tocopherol in beagle dogs.
Alipour, M; Bolger, G; Mitsopoulos, P; Pucaj, K; Smith, MG; Suntres, ZE, 2013
)
0.39
" At maximum dosage and time (15 μM and 96 h), Sorafenib-loaded PLGA and HMC-coated liposomes killed 88."( Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma.
Arora, J; Boonkaew, B; Callaghan, C; Chava, S; Dash, S; He, J; John, VT; Lee, BR; Liu, J; Maddox, MM; Mandava, SH, 2015
)
0.42
" These results were then correlated with the effects of alamethicin on biological membranes in vitro as observed by optical microscopy and microculture tetrazolium assay on the tumour cells HeLa to provide a comprehensive and quantitative analysis of these effects, based on a dose-response relationship."( Vertical ordering sensitivity of solid supported DPPC membrane to alamethicin and the related loss of cell viability.
Bordi, F; Castellano, C; Congiu, A; Dell'Unto, F; Domenici, F; Olmati, C; Tiezzi, A; Triggiani, D, 2015
)
0.42
" Liposomal (LE) antibiotics allow low-frequency dosing and extended efficacy compared with standard (STD) formulations."( A Novel Loading Method for Doxycycline Liposomes for Intracellular Drug Delivery: Characterization of In Vitro and In Vivo Release Kinetics and Efficacy in a J774A.1 Cell Line Model of Mycobacterium smegmatis Infection.
Franklin, RK; Heath, TD; Krugner-Higby, LA; KuKanich, BK; Marcus, SA; Sullivan, R; Talaat, AM, 2015
)
0.42
"The present study was designed to develop an efficient, safe, and patient-friendly dosage form, for oral delivery of alfa-choriogonadotropin, used in the treatment of female reproductive infertility."( Development and Characterization of Saturated Fatty Acid-Engineered, Silica-Coated Lipid Vesicular System for Effective Oral Delivery of Alfa-Choriogonadotropin.
Jobanputra, A; Nivsarkar, M; Saxena, B; Shah, V, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,048)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990341 (8.42)18.7374
1990's1031 (25.47)18.2507
2000's1262 (31.18)29.6817
2010's1218 (30.09)24.3611
2020's196 (4.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.71 (24.57)
Research Supply Index8.34 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (11.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials20 (0.48%)5.53%
Reviews46 (1.11%)6.00%
Case Studies3 (0.07%)4.05%
Observational0 (0.00%)0.25%
Other4,089 (98.34%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]